Investing.com -- GoodRx (NASDAQ:GDRX) stock fell 5% on Thursday after a CBS reporter indicated that the discount prescription drug platform would not be partnering with the upcoming TrumpRx initiative ...

Healthcare tech company GoodRx (NASDAQ:GDRX) reported Q3 CY2025 results , but sales were flat year on year at $196 million.

Healthcare may be evolving at lightning speed, but affordability remains the toughest pill to swallow. From breakthrough drugs to digital care, innovation keeps rewriting medical possibilities. Yet ...

While the top- and bottom-line numbers for GoodRx (GDRX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics ...

Discover key insights from GoodRx Q3 2025 earnings: strong manufacturer solutions growth, new pharma partnerships, and promising outlook.

GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," "GoodRx," or the "Company"), the leading platform for medication savings in the U.S., has released its financial results for the third quarter ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

GoodRx helps consumers find lower prescription prices via a platform that compares costs across pharmacies. The company's revenue includes fees from pharmacies and PBMs, plus earnings from advertising ...

GoodRx Holdings, Inc. ( GDRX) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx Third Quarter 2025 Earnings Call. As a ...